课题基金 / 基金详情

Immune Regulation by Deubiquitination

Immune Regulation by Deubiquitination
通过去泛素化进行免疫调节
批准号:
9982199
负责人:
Michael Croft
金额:
$45.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-19 至 2023-08-31

项目摘要

项目成果

Michael Croft的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Our long-term goal is to study the ubiquitin system in immune regulation. We initiated a new study of the deubiquitinating enzyme CYLD and found that deficiency of CYLD in T regulatory cells (Treg) caused chronic lung inflammation by increasing IL-4 production. These preliminary studies pointed to new mechanisms of CYLD regulation of Tregs, via modulating the cytokine production, and highlighted potential tissue-specific aspects of Treg function. Recently, we found that CYLD acts as a positive regulator in the differentiation of Treg to T follicular regulatory T cells (Tfr) in lymphoid tissues. These preliminary studies thus provide us with a solid basis for testing our central hypothesis that the ubiquitination/deubiquitination system plays a critical role in immune regulation via modulating different T cell subsets in tissue context-dependent manner. Here we plan to test this hypothesis by proposing two Specific Aims: Aim 1, to study CYLD in Treg regulation; and Aim 2, to study the role of CYLD in Tfr. The expected results will significantly advance our basic knowledge on the protein deubiquitination pathway in immune regulation, and will provide clues to therapeutic intervention of human diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TWEAK and Skin Inflammation
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
TWEAK and Skin Inflammation
海外基金